NCT06742853 - A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 20, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions

Dyslipidemia

Interventions

DRUG

AZD0780

AZD0780 tablet will be administered orally.

DRUG

Ezetimibe

Ezetimibe tablet will be administered orally.

DRUG

Rosuvastatin

Rosuvastatin tablet will be administered orally.

DRUG

Bempedoic Acid

Bempedoic Acid tablet will be administered orally.

DRUG

Placebo

Placebo will be administered orally.

Trial Locations (3)

Research Site, Brooklyn

Research Site, Glendale

Research Site, Harrow